Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells

Päivi Östling1, Suvi-Katri Leivonen, Anna Aakula

  • 1Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland. paivi.ostling@vtt.fi

Cancer Research
|February 24, 2011
PubMed

Insights

MicroRNAs regulate androgen receptor (AR) protein levels by targeting its extended 3'UTR in prostate cancer. This discovery offers new therapeutic strategies for inhibiting AR function and cell growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Androgen receptor (AR) is crucial in prostate cancer progression, even in castration-resistant stages.
  • Understanding AR regulatory mechanisms is key for developing effective therapies.
  • MicroRNAs (miRNAs) are implicated in cancer, but their role in AR regulation is not fully understood.

Purpose of the Study:

  • To systematically identify miRNAs that regulate AR protein levels in prostate cancer.
  • To investigate the role of the AR 3 UTR in miRNA-mediated regulation.
  • To explore the therapeutic potential of AR-regulating miRNAs.

Main Methods:

  • A gain-of-function screen of 1129 miRNAs in prostate cancer cell lines.
  • Quantification of AR protein levels using protein lysate microarrays.
  • RNA sequencing to analyze AR 3 UTR length and miRNA binding assays.

Main Results:

  • Identified 71 unique miRNAs influencing AR protein levels.
  • Revealed that the AR 3 UTR is significantly longer than previously recognized, with potential miRNA binding sites.
  • Validated 13 miRNAs targeting the extended AR 3 UTR, with 15 AR-downregulating miRNAs inhibiting androgen-induced proliferation.
  • Confirmed negative correlation between miR-34a/miR-34c expression and AR levels in clinical prostate cancer samples.

Conclusions:

  • miRNAs targeting the long AR 3 UTR are significant regulators of AR protein levels.
  • These findings have implications for novel therapeutic strategies targeting AR in prostate cancer.
  • Further research into miRNA-AR interactions could lead to new treatments for androgen-dependent prostate cancer growth.